Odyssey Therapeutics reports Q3 2026 results, updates OD-001 and OD-002 progress
The company cited new biomarker support for its ulcerative colitis drug and completed IND-enabling work for a second program, with cash seen lasting into the second half of 2028.
Odyssey Therapeutics reported financial results for the third quarter ended September 30, 2026, and gave an update on its pipeline on November 4, 2026.
In October, Odyssey presented additional findings from the Phase 2a induction period involving 56 efficacy-evaluable patients with moderate-to-severe ulcerative colitis at United European Gastroenterology (UEG) Week and shared new clinical and translational analyses during a company webcast.1 The company said the clinical efficacy results are supported by concordant findings across clinical outcomes and inflammatory biomarkers, mucosal transcriptomics, and histologic improvement, which it said reinforces the earlier proof-of-concept finding and adds biological evidence consistent with RIPK2 scaffolding inhibition.1
For OD-001, topline induction results from the Phase 2b monotherapy trial and the Phase 2a combination trial with vedolizumab are expected in the second half of 2027.1
Odyssey also completed IND-enabling studies for OD-002, which the company describes as a first-in-class oral SLC15A4 inhibitor. Following completion of those studies, the company plans to start a Phase 1/2a trial in the first half of 2027, beginning with healthy volunteers before moving into patient groups spanning several conditions, including cutaneous lupus erythematosus.1 The company expects to report healthy-participant data in the second half of 2027, including results from an ex vivo stimulation assay that it said has shown translational relevance to clinical efficacy seen in lupus trials of other TLR7/8-targeting agents.1
Odyssey also disclosed preclinical data plans for OD-003, a TNFR2 agonist, at the ACR Convergence 2026 meeting running November 6-11, and said it had selected a development candidate for OD-004, its TSLP/IL-33 bispecific antagonist, which it said has potency for both targets comparable to or better than existing monospecific agents, with the program moving into IND-enabling studies.1
On finances, Odyssey had $387 million in cash, cash equivalents and marketable securities as of September 30, 2026, which the company said is expected to fund operations into the second half of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.